



Contacts: Meg McGilley  
Chief Financial Officer  
(858) 509-3670

Rob Whetstone  
PondelWilkinson, Inc.  
(310) 279-5963

## Somaxon Pharmaceuticals To Present At The UBS Global Specialty Pharmaceuticals Conference

SAN DIEGO, CA – April 18, 2006 – Somaxon Pharmaceuticals, Inc., (NASDAQ: SOMX) today announced that Kenneth Cohen, President and Chief Executive Officer, will present a company update at the UBS Global Specialty Pharmaceuticals Conference in New York City on Tuesday, April 25, 2006 at 3:30 p.m. Eastern Time. The presentation will take place at the Grand Hyatt Hotel Ballroom E.

A live webcast of Mr. Cohen's presentation will be available in the Investor Relations section of the Company's website under Event Scheduler at [www.somaxon.com](http://www.somaxon.com). The webcast will be archived and accessible for at least 14 days.

### **About Somaxon Pharmaceuticals**

Headquartered in San Diego, CA, Somaxon Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on the in-licensing and development of proprietary product candidates for the treatment of diseases and disorders in the fields of psychiatry and neurology. Somaxon's lead product candidate, SILENOR™ (doxepin HCl), is in Phase 3 clinical trials for the treatment of insomnia. Nalmefene HCl is in a Phase 2/3 clinical trial for the treatment of pathological gambling and in a pilot Phase 2 trial for smoking cessation. Acamprosate Ca, a potential treatment for movement disorders, is currently in formulation development.

For more information, please visit the company's web site at [www.somaxon.com](http://www.somaxon.com).

*Somaxon cautions you that statements included in this press release or the presentation at the UBS Global Specialty Pharmaceuticals Conference that are not a description of historical facts are forward-looking statements. The inclusion of forward-looking statements should not be regarded as a representation by Somaxon that any of its plans will be achieved. Actual results may differ materially from those set forth in this release due to the risks and uncertainties inherent in Somaxon's business, including, without limitation: the results of*

*pending clinical trials; unexpected adverse side effects or inadequate therapeutic efficacy of SILENOR™ or Somaxon's other products that could delay or prevent regulatory approval or commercialization, or that could result in recalls or product liability claims; other difficulties or delays in development, testing, manufacturing and marketing of and obtaining regulatory approval for SILENOR™ or Somaxon's other product candidates; the market potential for Somaxon's target markets, and Somaxon's ability to compete; and other risks detailed in Somaxon's Annual Report on Form 10-K, filed with the SEC on March 22, 2006, and other periodic filings with the SEC.*

*You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement and Somaxon undertakes no obligation to revise or update this news release to reflect events or circumstances after the date hereof. This caution is made under the safe harbor provisions of Section 21E of the Private Securities Litigation Reform Act of 1995.*